Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...

Spinraza (nusinersen) is a prescription drug used to treat spinal muscular atrophy. Spinraza can cause side effects that range from mild to serious. Examples include headache and fever.

Sumitomo Mitsui Trust Group Inc. lessened its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 20.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor ...

In the fourth quarter, lower sales of BIIB's multiple sclerosis drugs and Spinraza are likely to have been offset by revenues from new drugs.

Royalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus ...

Biogen (NASDAQ:BIIB) stock traded flat as the company reports better than expected Q4 2024 financials, but its 2025 outlook ...

Spinraza, also known as nusinersen, is a medicine used to treat spinal muscular atrophy (SMA) in children and adults. SMA is a genetic disease that is passed down through families. It leads to ...

The FDA on Wednesday approved the industry’s first-ever tablet treatment for spinal muscular atrophy— Roche ’s SMN2 splicing ...

Biogen has bagged $250 million to advance a key pipeline prospect. | Biogen has bagged $250 million to advance a key pipeline ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Biosimilars sales were $201.5 million, up 7% driven by Benepali, with sales of $125 million, up 16%. LEQEMBI global in-market sales in the quarter were approximately $87 million, including U.S.

Biogen beat Q4 estimates with a 17% EPS rise and $2.46 billion in sales. The company expects revenue declines in 2025 as multiple sclerosis drug sales drop.